| abstract |
The peptide in this invention is a peptide having affinity to gp120 represented by Formula (1): H-A1-A2-A3-A4-A5-R n (in the formula, n H means hydrogen, n A1 is aspartic acid, lysine, valine, glutamic acid, glycine, asparagine, or tyrosine reidue, n A2 is valine, aspartic acid, tryptophan, lysine, phenylalanine, isoleucine, leucine, or tyrosine residue, n A3 is lysine, valine, aspartic acid, arginine, alanine, or tryptophan residue, n A4 is alanine, tryptophan, or glycine residue, n A5 is glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, asparagine, glutamine, histidine, lysine, arginine, phenylalanine, tryptophan, proline, or tyrosine residue, n R is OH derived from carboxyl group or NH2 derived from acid amide group). n The above peptide has an affinity to gp120 of the HIV envelope protein and is superior in stability. |